C07D213/32

ADO-resistant cysteamine analogs and uses thereof

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

HETEROCYCLIC COMPOUND

A compound represented by formula (I)

##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom;

##STR00002##

hereinafter referred to as “Het”, represents Het-1, Het-2, Het-3, or Het-4:

##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and

##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7:

##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

HETEROCYCLIC COMPOUND

A compound represented by formula (I)

##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom;

##STR00002##

hereinafter referred to as “Het”, represents Het-1, Het-2, Het-3, or Het-4:

##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and

##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7:

##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

HIGH-THROUGHPUT METHOD TO RAPIDLY ADD CHEMICAL MOIETIES TO A SMALL MOLECULE LIBRARY

Organic compounds for target identification, drug discovery, chemical library production, high-throughput screening, fluorophore conjugation, chemiluminescent compound conjugation, creation of proximity induced modulators (e.g., protein degraders)/chimeric molecules, or a combination thereof are described. The compounds can contain small molecule moieties for identification of their potential targets; an isocyanate, photoactivatable groups; chemical moieties for enrichment and detection of target-small molecule moiety interactions; proximity induced modulator element; fluorophores; chemiluminescent groups; or combinations thereof.

Heterocyclic compound

A compound represented by formula (I) ##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom; ##STR00002##
hereinafter referred to as “Het”, represents Het-1, Het-2, Het-3, or Het-4: ##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and ##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7: ##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

Heterocyclic compound

A compound represented by formula (I) ##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom; ##STR00002##
hereinafter referred to as “Het”, represents Het-1, Het-2, Het-3, or Het-4: ##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and ##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7: ##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

Substituted bicyclic compounds

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted bicyclic compounds

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.